NCT07222930

Learning Amyloid and Tau Results

Reactions to Learning Amyloid and Tau Results in Adults at Risk for Alzheimer's Dementia

• Status: Not Yet Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 240 (estimated)
• Sponsor: University of Wisconsin, Madison · Academic / Other
• Sex: All
• Age: 50 Years – 89 Years
• Healthy volunteers: Accepted

Summary

This is a prospective, single-cohort, single-center, observational study to assess if learning one's Alzheimer's disease biomarker test result impacts longitudinal psychosocial, behavioral, and neuropsychological outcomes, and to identify factors that moderate and mediate these outcomes. Participants enrolled in this study are requested to complete surveys at four timepoints after learning their Alzheimer's biomarker test results.

Detailed description

The overall objective is to determine how learning one's amyloid and tau test results impacts longitudinal psychosocial, behavioral, and neuropsychological outcomes, and identify factors that moderate and mediate these outcomes. The rationale is that by understanding factors that explain variability in reactions, biomarker communication and post-testing support can be tailored to optimize outcomes. The central hypothesis is that learning biomarker profile will affect psychosocial, behavioral, and neuropsychological outcomes, and that these outcomes will be moderated by social determinants of health (SDOH) and perceived communication factors and mediated by illness perceptions and beliefs.

Conditions

• Alzheimer Disease

Interventions

Type	Name	Description
OTHER	Disclose amyloid, tau results	Release of results from investigational agents conducted under IND 107114, IND 166860, and IND 134516
OTHER	Follow-up Assessments	self-report psychosocial and behavioral questionnaires

Timeline

• Start date: 2026-04-01
• Primary completion: 2029-06-01
• Completion: 2029-06-01
• First posted: 2025-10-30
• Last updated: 2026-03-12

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study